Latest news with #ZymeworksInc
Yahoo
09-05-2025
- Business
- Yahoo
Zymeworks Inc (ZYME) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Zymeworks Inc (NASDAQ:ZYME) reported a significant increase in revenue for Q1 2025, reaching $27.1 million compared to $10 million in the same period in 2024. The company achieved a decrease in net loss from $31.7 million in Q1 2024 to $22.6 million in Q1 2025, primarily due to increased revenue. Zymeworks Inc (NASDAQ:ZYME) has a strong cash position with $321.6 million in cash resources, expected to fund operations into the second half of 2027. The company presented six posters at the AACR annual meeting, showcasing progress in their antibody drug conjugate and T-cell engager pipeline. Zymeworks Inc (NASDAQ:ZYME) is eligible for significant milestone payments and royalties from partnerships, including up to $86 million in development milestones and $373 million in commercial milestone payments from J&J. Operating expenses increased by 10% to $52.7 million in Q1 2025 compared to $47.3 million in Q1 2024. Research and development expenses rose to $35.7 million in Q1 2025 from $32 million in Q1 2024, driven by increased preclinical research expenses. General and administrative expenses increased to $17 million in Q1 2025 from $15.8 million in Q1 2024, primarily due to higher stock-based compensation. The company faces uncertainties related to the approval of Zanadatimab for HER2+ biliary tract cancer, which could impact future royalty revenues. Zymeworks Inc (NASDAQ:ZYME) has not provided specific guidance on the timing of data releases for key clinical programs, which may concern investors seeking near-term updates. Warning! GuruFocus has detected 5 Warning Signs with ZYME. Q: As you prioritize assets and indications for development, what are your base case assumptions regarding milestone and royalty revenues from assets like zanidatamab? How do these factor into your prioritizations? A: Ken Galbraith, CEO, emphasized the importance of capital allocation and clinical execution. He noted that they are excited about the progress of zanidatamab with partners Jazz and BeiGene, and they are looking forward to the Horizon GEA01 data results. The company will make appropriate capital allocation decisions with their board as they receive additional capital from milestones or other sources. They are also encouraged by the progress of technology partnerships, such as the collaboration with Johnson & Johnson on the KLK2 CD3 T-cell engager. Q: Can you provide insights on the cytokine induction data for ZW 209, especially in relation to cytokine release syndrome? A: Dr. Paul Moore, Chief Scientific Officer, explained that ZW 209 is designed to engage CD3, CD28, and DLL-3, with CD28 engagement only occurring when CD3 is engaged. This design limits the activation of T-cells and reduces the potential for broad cytokine release. The molecule's design aims to provide a therapeutic benefit by increasing the therapeutic index with a balanced, localized impact on T-cells. Q: Regarding the phase 3 Horizon GA study, how might ex-US patients impact the powering and outcome on PFS and OS? A: Ken Galbraith, CEO, stated that generally, there is not a significant difference in efficacy across ethnicities in clinical studies. While there was a slight difference in the KEYNOTE-811 study between Asian and non-Asian subjects, it is not clear what to make of it. The Horizon GA study includes a diverse global patient population, and they will rely on KOLs to interpret any subpopulation differences. Q: What are your expectations for the prostate update at ASCO regarding the J&J KLK2 bispecific with CD3? A: Ken Galbraith, CEO, mentioned that the collaboration with J&J involves their asymmetric platform, and they are entitled to milestones based on development progression and mid-single-digit royalties on sales. They are looking forward to the ASCO presentation and J&J's intentions for the program, which could be significant for both companies. Q: How many programs can Zymeworks support in early development internally, and what is the gating factor for external collaborations? A: Ken Galbraith, CEO, stated that they can handle about five internal programs through phase one and about ten pre-clinical programs at any one time. They evaluate partnerships regularly to potentially advance programs more quickly and efficiently. They are comfortable with their current pace and will consider collaborations to advance additional programs without requiring significant capital investment. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at About Zymeworks Inc. Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on X. Contacts: Investor Inquiries:Shrinal InamdarSenior Director, Investor Relations(604) 678-1388ir@ Media Inquiries:Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@ in to access your portfolio
Yahoo
09-04-2025
- Business
- Yahoo
Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump's Tariff Rollout
We recently published a list of . In this article, we are going to take a look at where Zymeworks Inc. (NASDAQ:ZYME) stands against other stocks that insiders bought in April after Trump's tariff rollout. President Donald Trump called April 2 a 'Liberation Day' after signing an executive order that imposed a minimum 10% tariff on all U.S. imports, with some exceptions. As a result, 57 countries will face higher tariffs ranging from 11% to 50%. While general tariffs took effect on April 5, the elevated rates are set to begin on April 9. These so-called 'reciprocal tariffs' triggered retaliation from trade partners and contributed to a decline in the stock market.' On Sunday, Trump said, 'I don't want anything to go down, but sometimes you have to take medicine to fix something,' as reported by CNBC. The blue-chip companies closed the Monday market session 0.91% lower, while the broader market index closed 0.23% lower after briefly entering bear market territory during the session. The Nasdaq Composite closed 0.10% higher. Amid these tariff wars and overwhelming market uncertainty, insider trading often comes to focus. Why? When executives buy stock, it can suggest confidence in the company's future. On the other hand, insider sales don't have to be a negative sign for the company, because they can reflect personal decisions or investment diversification. This means that insider trading should be considered alongside the company's financial health and market conditions. Today, we're focusing on stocks that insiders have been buying in April. Using Insider Monkey's insider trading screener, we identified companies where at least one insider acquired shares from April 2 to April 7. From this list, we ranked the top 20 stocks with the highest value of insider purchases. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A researcher in a lab holding a bispecific antibody, illustrating the leading edge of cancer treatments. Zymeworks is a clinical-stage biopharmaceutical company that develops cancer treatments, with its lead candidates including zanidatamab, a HER2-targeted therapy in Phases 1-3 of clinical trials, and zanidatamab zovodotin, a Phase 2 antibody-drug conjugate. The company, based in Middletown, Delaware, is also exploring preclinical oncology programs and collaborating with major partners like BeiGene, Celgene, GlaxoSmithKline, and Merck Sharp & Dohme. In April, one insider bought $3.62 million worth of Zymeworks shares at an average price of $11.51 per share. Year-to-date, the stock is down 27.94% trading at $10.55 per share. Over the past 12 months, Zymeworks returned 9.67%. For the full year 2024, Zymeworks reported revenue of $76.3 million, slightly up from $76.0 million in 2023. The revenue included $25.0 million in milestone payments from Jazz related to the FDA approval of Ziihera for HER2+ BTC treatment. The company incurred $134.6 million in research and development expenses, down from $143.6 million in 2023, and posted a net loss of $122.7 million, compared to a $118.7 million loss the previous year. As of December 31, Zymeworks held $324.2 million in cash, cash equivalents, and marketable securities. According to MarketBeat, eight analysts rate Zymeworks stock as a 'Moderate Buy' with a price target of $21.00. The average price target suggests an upside of 98.58% from the latest price. Overall, ZYME ranks 9th on our list of stocks that insiders bought in April after Trump's tariff rollout. While we acknowledge the potential of ZYME, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZYME but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
Analysts Just Shipped A Captivating Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
Zymeworks Inc. (NASDAQ:ZYME) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects. Following the upgrade, the current consensus from Zymeworks' seven analysts is for revenues of US$95m in 2025 which - if met - would reflect a huge 25% increase on its sales over the past 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 20% to US$1.40. However, before this estimates update, the consensus had been expecting revenues of US$84m and US$1.61 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates. View our latest analysis for Zymeworks Despite these upgrades, the analysts have not made any major changes to their price target of US$19.61, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Zymeworks' revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 25% growth on an annualised basis. This is compared to a historical growth rate of 33% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 20% annually. So it's pretty clear that, while Zymeworks' revenue growth is expected to slow, it's expected to grow roughly in line with the industry. The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Zymeworks is moving incrementally towards profitability. They also upgraded their revenue forecasts, although the latest estimates suggest that Zymeworks will grow in line with the overall market. The lack of change in the price target is puzzling, but with a serious upgrade to this year's earnings expectations, it might be time to take another look at Zymeworks. Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Zymeworks analysts - going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
06-03-2025
- Business
- Yahoo
Zymeworks Inc (ZYME) Q4 2024 Earnings Call Highlights: Strategic Shifts and Financial Insights
Net Loss: $122.7 million for the year-ended December 31, 2024, compared to $118.7 million in 2023. Revenue: $76.3 million for the year-ended December 31, 2024, compared to $76 million in 2023. Partnership Earnings: Over $45 million earned from partnerships in the past 12 months. Cash Resources: $324.2 million as of December 31, 2024, compared to $456.3 million as of December 31, 2023. Operating Expenses: $213.4 million for the year-ended December 31, 2024, compared to $214.1 million in 2023. Other Income, Net: $20.5 million for the year-ended December 31, 2024, compared to $18.8 million in 2023. Shares Outstanding: Approximately 69.6 million shares of common stock and 5.1 million shares issuable under prefunded warrants. Research Milestone from GSK: $14 million achieved in January 2025. Net Product Sales by Jazz: $1.1 million in Q4 2024. Warning! GuruFocus has detected 5 Warning Signs with ZYME. Release Date: March 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Zymeworks Inc (NASDAQ:ZYME) reported a successful quarter marked by the approval of zanidatamab and progress in clinical development. The company has earned over $45 million from partnerships in the past 12 months, highlighting the strength of its collaborations. Zymeworks Inc (NASDAQ:ZYME) has a strong financial position with $324.2 million in cash resources, providing a cash runway into the second half of 2027. The company is expanding its focus into autoimmune and inflammatory diseases, as well as hematological oncology, reflecting its commitment to innovation. Zymeworks Inc (NASDAQ:ZYME) has initiated two global Phase I clinical trials for ZW171 and ZW191, with steady progress in patient recruitment across multiple regions. Zymeworks Inc (NASDAQ:ZYME) reported a net loss of $122.7 million for the year-ended December 31, 2024, an increase from the previous year. The increase in net loss was primarily due to a $17.3 million noncash impairment charge related to zanidatamab, zovodotin. Revenue for 2024 was relatively flat compared to 2023, with only a slight increase from $76 million to $76.3 million. The company decided to discontinue the zanidatamab, zovodotin clinical development program, resulting in a noncash impairment charge. Zymeworks Inc (NASDAQ:ZYME) experienced a decrease in cash resources from $456.3 million as of December 31, 2023, to $324.2 million as of December 31, 2024. Q: On ZW251, should we expect an urgency to initiate combination cohorts quicker than for other compounds? A: Kenneth Galbraith, CEO: We have the same strategy for the entire portfolio, focusing on early signs of tumor activity. We believe ADCs and T cell engagers used in combination with standard-of-care might create sustainable responses. For ZW251 in HCC, given the poor prognosis, we aim to study it in dose escalation and then in combination cohorts for stronger outcomes. Q: What prompted the prioritization of ZW251 over ZW220? A: Kenneth Galbraith, CEO: We actively manage our portfolio and prioritize based on resource allocation. We are excited about ZW251 and have accelerated its clinical studies. ZW220 remains interesting and is IND-ready, but our focus is on ZW251 due to its potential impact on a different patient population. Q: Is the delay in the HERIZON-GEA-01 trial readout due to slower enrollment or event rate accumulation? A: Kenneth Galbraith, CEO: We can't speculate on clinical data specifics. Jazz provided guidance on the trial's timing and rationale. I refer you to their recent updates for more details. Q: Was there a standout result in ZW251's preclinical work that influenced its prioritization? A: Kenneth Galbraith, CEO: We always seek to accelerate clinical studies. ZW251's preclinical data, particularly in HCC models, has been exciting and supports our decision to prioritize it. We aim to bring it to patients as soon as possible. Q: What are the gating factors for filing the IND for ZW1528 in autoimmune and inflammatory diseases? A: Paul Moore, CSO: We are excited about ZW1528's preclinical profile. We need to complete IND-enabling activities, including tox study plans and material preparation. We aim for a realistic timeline, targeting the second half of 2026. Q: How does ZW191's linker stability compare to competitors, and what is its expected toxicity profile? A: Paul Moore, CSO: Our linker stability is traditional, avoiding highly stable linkers. We focus on a tolerable profile to allow higher dosing and combination strategies. Preclinical data supports this approach, aiming for a more efficacious response. Q: How are you thinking about data disclosure for ZW171 and ZW191? A: Kenneth Galbraith, CEO: We will provide updates at peer-reviewed meetings once we have meaningful data. The studies are progressing well, and we aim to present data that is significant and informative. Q: Can you share thoughts on multi-payload ADCs? A: Paul Moore, CSO: We consider multi-payload ADCs and are investigating additional payloads. The decision depends on the therapeutic rationale and the biology of the target indication. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
